A large US study published in The BMJ compared buprenorphine and methadone use during pregnancy for treating opioid addiction, examining neurodevelopmental outcomes in children. The research found that children born to mothers who used buprenorphine show no greater risk of neurodevelopmental disorders including ADHD and autism compared to children whose mothers took methadone. The findings provide important reassurance for pregnant women with opioid addiction and their healthcare providers about choosing buprenorphine as a treatment option. This evidence addresses critical safety concerns about medication-assisted treatment during pregnancy, a period when managing opioid addiction is essential for both maternal and fetal health.
Buprenorphine safety compared to methadone during pregnancy
- ▪Children born to mothers who used buprenorphine for opioid addiction during pregnancy do not have a greater risk of neurodevelopmental disorders compared with children whose mothers took methadone
- ▪A large US study published by The BMJ compared buprenorphine and methadone use during pregnancy for opioid addiction treatment
Neurodevelopmental outcomes in children exposed to opioid treatment
- ▪The BMJ study examined neurodevelopmental disorders including ADHD and autism in children exposed to opioid addiction treatment during pregnancy
Perspective of Pregnant women with opioid addiction and their healthcare providers
- ▪The BMJ study findings provide reassurance about buprenorphine as a critical treatment option for opioid addiction during pregnancy
- ▪Buprenorphine is considered a safe medication for treating opioid addiction in pregnant women based on the study results
Story comments
Loading comments…